What are Aclaris Therapeutics's profit margins?

Aclaris Therapeutics (ACRS) runs a 76.3% gross margin and a -961.9% operating margin, with a -832.6% net margin.

Where do Aclaris Therapeutics's ratios come from?

Every ratio is computed from Aclaris Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.

Aclaris Therapeutics ACRS Ratios & Valuation

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Profitability
Gross margin	73.3%-11.8pp	85.1%-4.0pp	89%+2.6pp	86.5%+56.2pp
Operating margin	-975.9%-218pp	-758.1%-447pp	-311.6%-9.5pp	-302%+1,025pp
Net margin	-829.6%-124pp	-705.4%-422pp	-283.1%+9.0pp	-292.1%+1,052pp
Returns
Return on equity	-50.2%+34.3pp	-84.5%-34.6pp	-49.9%-5.9pp	-44%+33.3pp
Return on invested capital	-69.8%+41.8pp	-111.6%-40.9pp	-70.7%-15.8pp	-54.9%+33.7pp
Efficiency
Asset turnover	0×0.0×	0.1×0.0×	0.1×0.0×	0.1×+0.1×
Liquidity
Current ratio	3.4×-0.6×	4×-0.2×	4.2×-6.4×	10.6×+1.6×
Leverage
Debt-to-equity	0×0.0×	0×0.0×	0×0.0×	0×0.0×
Per Share
Book value per share	$0.84-58.2%	$2.01-10.6%	$2.25-25.7%	$3.03-12.9%
Valuation
Market capitalization	$685.75M+337%	$265.41M+257%	$74.38M-92.9%	$1.05B+18.0%
Price / sales	82×+73.1×	14.2×+11.8×	2.4×-32.9×	35.3×-96.4×
Price / book	4.8×+3.7×	1.7×+1.2×	0.5×-4.8×	5.3×+0.8×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Aclaris Therapeutics.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Aclaris Therapeutics's profit margins?: Aclaris Therapeutics (ACRS) runs a 76.3% gross margin and a -961.9% operating margin, with a -832.6% net margin.
Where do Aclaris Therapeutics's ratios come from?: Every ratio is computed from Aclaris Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.